Building a roadmap for developing combination therapies for Alzheimer's disease

Daniel Perry, Reisa Sperling, Russell Katz, Donald Berry, David Dilts, Debra Hanna, Stephen Salloway, John Q. Trojanowski, Chas Bountra, Michael Krams, Johan Luthman, Steven Potkin, Val Gribkoff, Robert Temple, Yaning Wang, Maria C. Carrillo, Diane Stephenson, Heather Snyder, Enchi Liu, Tony WareJohn Mckew, F. Owen Fields, Lisa J. Bain, Cynthia Bens

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalExpert Review of Neurotherapeutics
Issue number3
StatePublished - Mar 1 2015
Externally publishedYes


  • Alzheimer' disease
  • co-development
  • collaboration
  • combination therapy
  • novel therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Building a roadmap for developing combination therapies for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this